Journal Article with Summary

Journal Article:

nejmra1502863

Summary:

Daniel DeMarco                  Journal Article Assignment                         Rotation #5: Peds

 

Eosinophilic Esophagitis

Glenn T. Furuta, MD and David A Katzka MD

New England Journal of Medicine

 

What is it?:

  • “Chronic, immune-mediated or antigen-mediated esophageal disease characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation”
  • Predominant antigens = food-based antigens

 

Epidemiology?:

  • Western World prevalence estimate = 0.4% of all children and adults
  • Increasing prevalence in Asia
  • Male predominance: 3:1; predominantly white men with onset from school age to midlife
  • Factors associated with increased risk of eosinophilic esophagitis (EOE): birth by C-section, prematurity, antibiotic exposure during infancy, food allergy, lack of breast-feeding, living in areas of lower population density, personal or family history of atopic disorders: asthma, eczema, rhinitis, anaphylactic food allergy
  • Genetic Component = family history of EOE, three genes altered in EOE based on genome studies
  • Co-existing conditions = connective-tissue disease, celiac disease, Crohn’s disease

 

Symptoms?:

  • In Children?: feeding problems, failure to thrive, vomiting, nausea, heartburn, abdominal pain
  • In Adolescents and Adults?: dysphagia, food impaction
  • In All?: chronic reflux symptoms

 

DDx?:

  • GERD
  • Parasitic infection
  • Allergic vasculitis
  • Esophageal leomyomatosis
  • Crohn’s disease

 

Pathogenesis?:

  • Combination of:
    • Impaired Barrier Function: dilated interepithelial spaces, altered epithelial barrier function, down-regulation of proteins with barrier function which alter the epithelial permeability = increased antigen presentation = increased recruitment of eosinophils
    • Enhanced TH2 Activity and Allergic Susceptibility
    • IL-5 and IL-13: treatment with anti-IL5 and IL-13 antibodies decreases esophageal eosinophils in children and adults
    • Food-specific IgG4

 

Procedures/Imaging?:

  • Upper Endoscopy + Biopsy
  • Intraluminal Balloon Device to measure wall compliance
  • Contrast Esophagography

 

Endoscopic Findings?:

  • “White Specks” = eosinophilic exudates
  • Mucosal edema
  • Linear furrows
  • Esophageal rings
  • Strictures
  • “Crepe-Paper Esophagus” = linear tears 2’ to trauma
  • “Tug Sign” = firm feeling felt by endoscopist
  • Development of validated endoscopic scoring system = EREFS
    • Edema
    • Rings
    • Exudates
    • Furrows
    • Strictures

 

Barium Esophagography?:

  • Strictures/narrowing may not be detected on endoscopy = often there is evidence of this on barium esophagography

 

Findings on Histology?:

  • Hallmark = Esophageal mucosa with > or = to 15 eosinophils per high-power field
    • Sensitivity = 100%
    • Specificity = 96%
  • Other:
    • Aggregates of eosinophils = microabscess
    • Eosinophil layers along luminal surface
    • Dilated intercellular spaces
    • Rete-peg elongation
    • Basal-cell hyperplasia
    • Increased number of other inflammatory cells = lymphocytes, mast cells, basophils

 

Complications:

  • Esophageal stricture
  • Food impaction
  • Perforation
  • Malnutrition
  • EOE IS NOT PRE-MALIGNANT

 

Treatment:

  • Goals = alleviate symptoms, control inflammation, restore function
  • Modalities = diet, drugs, dilation
  • Team = gastroenterologist, allergist, nutritionist
  • Diet
    • Amino-acid based formula (elemental diet)
    • Allergen-targeted diets
    • Six-food elimination: wheat, milk, soy, nuts, eggs, seafood
    • Challenges: inc. cost of food, poor adherence, nutritional deficiencies
  • Drugs
    • Proton Pump Inhibitors = decrease cytokine secretion from esophageal epithelium possibly conferring anti-inflammatory effect
      • “Proton-pump inhibitor-responsive EOE”
    • Topical Glucocorticoids = decrease inflammatory cells, decrease fibrosis, reversal of IL-13 and EOE transcriptome
      • Fluticasone orally (MDI)
      • Budesonide orally (Viscous Liquid)
    • S/E: local candida infection, adrenal axis suppression, bone demineralization, diminished growth
  • Dilation
    • Alleviation of esophageal narrowing
    • No effect on inflammatory process